Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 233 forskning & utveckling 113 cancer 108 hjärta/kärl 86 diabetes 63 andningsvägar 29 mage/tarm 14 neurovetenskap 11 fda 9 delårsrapport 8 onkologi 8 seroquel 7 astma 7 forskning 7 infektion 7 akut kranskärlssjudom 6 medimmune 6 Observationsstudie 6 bokslutsrapport 5 naloxegol 5 forxiga 5 ledning 5 egfr-testning 5 motavizumab 5 RWE 5 influensavaccin 5 vandetanib 5 olaparib 4 fostamatinib 4 antibiotika 4 tc-5214 4 fluenz 4 Tagrisso 4 bristol-myers squibb 4 karolinska institutet 4 seroquel xr 4 ledgångsreumatism 4 anders ekblom 4 CVD-REAL 3 slusg 3 selumetinib 3 osimertinib 3 styrelsen 3 egentlig depression 3 subvention 3 vimovo 3 pathos 3 kroniskt obstruktiv lungsjukdom 3 astra tech 3 produkt 3 crestor® 3 gefitinib 3 japan 3 antibiotikaresistens 3 lungcancer 3 astrazenca 2 mdd 2 ticagrelor 2 typ2diabetes 2 samarbete 2 individanpassad behandling 2 saturn 2 kina 2 epanova 2 acalabrutinib 2 klopidogrel 2 caprelsa 2 entocort 2 registerstudie 2 ardea biosciences 2 opioider 2 patenttvist 2 slusg stipendium 2 seroquel xl 2 tyskland 2 byetta 2 recentin 2 kvartalsrapport 2 almedalen 2 Brilique 2 confirm 2 läkemedelsförmånen 2 esc 2 bydureon 2 targacept 2 Real World evidence 2 fulvestrant 2 life science 2 smärta 2 benralizumab 2 axanum 2 seroquel xr (quetiapin fumarat) 2 återfall 2 healthy heart africa 1 biokemiska markörer 1 ann cairns 1 sommarforskarskola 1 svenska lungcancerstudiegruppen 1 beslut 1 2009 annual scientific meeting in philadelphia 1 egfr-muterad 1 tobias ankner 1 bioläkemedel 1 bypass 1 läkemedel 1 skelettmetastaser 1 non-executive director 1 hha 1 flumist 1 tlv 1 lesinurad 1 blogg 1 skl 1 durvalumab 1 internationell konkurrens 1 formuleringspatent 1 exenatide 1 målstyrt läkemedel 1 kombiglyze xr 1 mikael agaton 1 ny indikation 1 stroke 1 pegasus 1 patent 1 barninfluensavaccin 1 osimertinub 1 influensanässpray 1 u.s. food and drug administration (fda) 1 zibotentan 1 berzeliussamlingen 1 generiskt esomeprazolmagnesium 1 sponsring 1 eurika 1 karin norlén 1 aks 1 kemi 1 pris läkemedel 1 asco 1 zactima (vandetanib) 1 anläggningar 1 styrelseordförande 1 produktion 1 DAISY 1 typ 2-diabetes 1 blodsockerkontroll 1 avancerad hormonkänslig bröstcancer 1 mrsa 1 lund 1 syntetisk kemi 1 stipendieprogram 1 r&d 1 nässprayvaccin 1 den amerikanska läkemedelsmyndigheten 1 förstoppning 1 dapagliflozin 1 apotex inc (notice of compliance 1 lesinurab 1 forsknings - och utvecklingscentra 1 årsredovisning 2011 1 immunoterapier 1 tre strategiska centra 1 komboglyze 1 moventig 1 mcrc 1 kolorektalcancer 1 ldl-c 1 dow jones sustainability index 1 inflammation 1 nytt läkemedel lungcancer 1 grymt fett 1 hjärt-och kärlsjukdom 1 pluto-studien 1 patologi 1 first studien 1 avancerad bröstcancer 1 egfr mutation 1 forskningsportfölj 1 högkostnadsskyddet 1 läkemedelstillverkning 1 kastrationsresistent 1 moderna therapeutics 1 journal of clinical oncology 1 hans andersson 1 päivi tolstoy 1 ceftarolinfosamil 1 lif 1 ordnat införande Almedalen 1 hypoglykemi 1 EGFR 1 stöd 1 kronisk smärta 1 antaros 1 fas 3-studie 1 sekundärprevention 1 citizens petition 1 hälsoekonomiska data 1 anastrozol 1 arbetsmarknadsdagar 1 motivationsstöd 1 Lynparza 1 ovarian cancer 1 bakterier 1 varumärkta generika 1 ämnesomsättningssjukdomar (emdac) 1 kol 1 vaccinet 1 roger henriksson 1 bröstcancer utmärkelse 2012 1 astrazeneca lund 1 hudinfektioner 1 forskarstipendium 1 myalept 1 pressmaterial 1 azd9773 1 sumitomo 1 stipendier 1 alzheimers 1 vimovotm 1 non-small cell lung cancer 1 bevacizumab 1 Uppsala Clinical Research Center 1 konkurrenskraften 1 opioidbehandling 1 usa 1 lipodystrofi 1 citizen petitions 1 e-brilique 1 CVD-REAL Nordic 1 produktionsanläggning 1 jonas bergh 1 jan lundberg 1 denosumab 1 bioventurehub 1 noc) 1 blodförgiftning 1 läkemedelsforskning 1 kanadensiska hälsovårdsministeriet 1 subventioner 1 cancerregister 1 max planck institute 1 corporate 1 hälsoekonomi 1 kranskärlsjukdom 1 h1n1 1 mobiltelefonapplikation 1 per hamid ghatan 1 pfizer 1 lungcancersymtom 1 caz-avi 1 tonårshjärnan 1 metabola sjukdomar 1 telekonferens 1 biohub 1 antidepressiva läkemedel 1 farxiga 1 läkemedelsforskningen 1 cediranib 1 generiska läkemedel 1 behandling lungcancer 1 toprol-xl 1 skatteärende 1 invasiv behandling 1 cardiologföreningen 1 kyntheum 1 non-small-cell lungcancer 1 vnr 1 glp-1 agonister 1 blodsockerfall 1 savor 1 gonorré 1 SUPPORT-studien 1 certriad 1 monoterapi 1 Imfinzi 1 hormonresistent 1 scilifelab 1 livskvalitet lungcancer 1 david brennan 1 prismodell 1 atac 1 karolinska universitetssjukhuset 1 astma/kol 1 kvalitetsregister 1 elisabeth björk 1 prevention 1 arimidex 1 patientstöd 1 artros 1 influensa 1 zinforo 1 translationell 1 leif johansson 1 quetiapin fumarat 1 per alfredsson 1 faslodex (fulvestrant) 1 mobil-app 1 patient websida 1 sepsis 1 pegasus-timi 1 delårsrapport januari-september 2011 1 mjukdelsinfektioner 1 hjärinfarkt 1 hjärtinfarkt 1 klinisk forsk 1 egfr positiv 1 nytt läkemedel mot lungcancer 1 advaxis 1 medicon village 1 QTERN 1 exacerbationer 1 årsredovisning 2010 1 eu 1 hjärtkärlhälsa 1 pozen 1 nda 1 forskare 1 SvFP 1 merck-avtal 1 alzheimers sjukdom 1 ämnesomsättningssjukdomar 1 the medicines company 1 brodalumab 1 nikotinkanalsblockerare 1 stemi 1 säsongsinfluensavaccin för barn som nässpray 1 metreleptin 1 årets kvinnliga ledare 1 complete response letter (crl) 1 collaboration 1 avastin 1 depression 1 nsaid 1 xigduo 1 magnus björsne 1 mölndal 1 torrent pharma 1 american college of rheumatology 1 psoriasis 1 NSCLC 1 sustainable brands 2011 1 cytofab 1 kvadrivalent 1 UCR 1 Zavicefta 1 forskarkarriärer 1 amend 1 oic 1 rosuvastatinkalcium 1 amylin 1 äggstockscancer 1 registreringsansökan 1 budesonid 1 diagnostik 1 jupiter-studien 1 jupiter 1 rosuvastatin 1 hyperkolesterolemi 1 merck 1 viktökning 1 schizofreni 1 apollo 1 amylin pharmaceuticals 1 pa 1 norge 1 debatt 1 nya läkemedel 1 iressa 1 grymt fett en filmserie om tonårshjärnan 1 renaissance 5 1 gensekvensering 1 sjukhussjuka 1 remissvar prismodell 1 illumina 1 fluenz tetra 1 delårsrapport januari - mars 1 pascal soriot 1 innovation 1 halvårsresultat 1 ipass 1 mdr-tb 1 right honourable baroness shriti vadera 1 pet 1 renaissance 4 1 sjukhusinfektioner 1 säsongsinfluencavaccin 1 akuta koronara syndrom 1 södertälje 1 yngre forskare 1 strategiska centra 1 antibiotikum 1 produktionschef 1 världsdiabetesdagen 2014 1 saxagliptin 1 hållbar utveckling 1 halvårsrapport 1 nktr-118 1 gikt 1 socialminister 1 opioidorsakad 1 gener 1 patientundersökning 1 Visa alla taggar

Senaste nytt

Media no image
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Pressmeddelanden   •   Nov 15, 2017 08:01 CET

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Benralizumab får positivt CHMP-utlåtande i EU  för behandling av svår, okontrollerad eosinofil astma
AstraZeneca PLC:s resultatrapport för första nio månader och tredje kvartalet 2017
AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

Pressmeddelanden   •   Nov 08, 2017 08:02 CET

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

AstraZeneca provides update on tralokinumab Phase III Programme in severe, uncontrolled asthma
FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom

FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom

Pressmeddelanden   •   Okt 31, 2017 18:23 CET

AstraZeneca och dess FoU-center för hematologi, Acerta Pharma, meddelar idag att den amerikanska läkemedelsmyndigheten FDA har godkänt Calquence(acalabrutinib) inom ramen för så kallat ”påskyndat godkännande” Calquence är en tyrosinkinashämmare och indikationen gäller behandling av vuxna patienter med mantelcellslymfom (MCL) som har fått minst en tidigare behandling. 1

 AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

Pressmeddelanden   •   Okt 31, 2017 08:14 CET

​AstraZeneca and MedImmune, its global biologics research and development arm, today announced the expansion of their clinical collaboration with Incyte Corporation.

AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission

AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission

Pressmeddelanden   •   Okt 23, 2017 08:14 CEST

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US today announced that they have submitted a new drug application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Lynparza(olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with a decision expected in the second half of 2018.

US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes

US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes

Pressmeddelanden   •   Okt 23, 2017 08:06 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise

US FDA accepts regulatory submission for  Lynparza in metastatic breast cancer and  grants priority review

US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants priority review

Pressmeddelanden   •   Okt 18, 2017 08:03 CEST

Lynparza has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer Regulatory submission acceptance is first for a PARP inhibitor beyond ovarian cancer

US FDA accepts supplemental biologics license application for Imfinzi in locally advanced unresectable non-small cell lung cancer

US FDA accepts supplemental biologics license application for Imfinzi in locally advanced unresectable non-small cell lung cancer

Pressmeddelanden   •   Okt 17, 2017 08:05 CEST

Imfinzi granted Priority Review Acceptance follows FDA’s Breakthrough Therapy Designation

Media no image

AstraZeneca shares its comprehensive scientific approach at the World Conference on Lung Cancer 2017

Pressmeddelanden   •   Okt 16, 2017 08:05 CEST

​Early-stage disease - Quality-of-life results from the Imfinzi Phase III PACIFIC trial headline the Presidential Symposium Overcoming treatment resistance - Novel combination of Tagrisso and savolitinib provide potential new options for EGFRm patients with MET resistance

The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer

The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer

Pressmeddelanden   •   Okt 09, 2017 08:06 CEST

AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced that the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Imfinzi (durvalumab) for the treatment of patients with locally-advanced (Stage III), unresectable non-small cell lung cancer

Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer

Tagrisso granted breakthrough therapy designation by US FDA for the 1st-line treatment of patients with EGFR mutation-positive non-small cell lung cancer

Pressmeddelanden   •   Okt 09, 2017 08:05 CEST

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Media no image

TAGRISSO INGÅR I LÄKEMEDELSFÖRMÅNERNA

Pressmeddelanden   •   Okt 03, 2017 14:56 CEST

Tandvårds- och läkemedelsförmånsverket, TLV, har beslutat att AstraZenecas läkemedel Tagrisso® (osimertinib) från och med den 1 oktober ingår i läkemedelsförmånerna för vuxna patienter med lokalt avancerad eller metastaserad epidermal tillväxtfaktorreceptor (EGFR) T790M mutationspositiv icke-småcellig lungcancer (NSCLC).

Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD

Bevespi Aerosphere demonstrates statistically significant improvement in lung function in patients with COPD

Pressmeddelanden   •   Sep 25, 2017 08:03 CEST

hase III, PINNACLE 4 trial demonstrates positive top-line results compared to its monotherapy components and placebo Trial supports filing of new drug applications in Japan and China​

Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk

Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk

Pressmeddelanden   •   Sep 14, 2017 18:27 CEST

​Largest and most inclusive patient population of any GLP-1 CV outcomes trial with 14,500 patients at 687 trial sites across 35 countries Full trial results presented at the annual meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in the New England Journal of Medicine

AstraZeneca and Aspen enter agreement for remaining rights to anaesthetic medicines

AstraZeneca and Aspen enter agreement for remaining rights to anaesthetic medicines

Pressmeddelanden   •   Sep 14, 2017 08:03 CEST

Agreement builds on 2016 collaboration on commercialisation rights to anaesthetic medicines in markets outside the US

AstraZeneca presents new results identifying severe asthma patients who would benefit most from Benralizumab

AstraZeneca presents new results identifying severe asthma patients who would benefit most from Benralizumab

Pressmeddelanden   •   Sep 11, 2017 10:11 CEST

Further analysis of the Phase III trials, SIROCCO and CALIMA, reinforces benralizumab’s efficacy and identifies more frequent prior exacerbations and/or greater baseline blood eosinophil count as key predictors of an enhanced treatment effect. Findings pave the way for a personalised treatment approach to guide more precise selection of the benralizumab-responsive patient.